[Chemotherapy-induced cardiac toxicity and management]

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Cardiac toxicity is a known complication of anti-neoplastic agents, first recognized with doxorubicin in the 1970s.
• While less frequent than other toxicities, cardiac damage can be irreversible, necessitating careful management.
• Modern treatments like high-dose chemotherapy with G-CSF, stem cell transplantation, and mediastinal irradiation exacerbate cardiac risks.

Purpose of the Study:

• To review the cardiac toxicity associated with anthracyclines and trastuzumab.
• To discuss current strategies for managing chemotherapy-induced cardiotoxicity.
• To emphasize the importance of cardiac function monitoring in cancer patients.

Main Methods:

• Literature review of cardiac toxicity from anthracyclines and trastuzumab.
• Analysis of management approaches for anti-neoplastic agent-induced cardiotoxicity.
• Discussion of monitoring techniques for cardiac function.

Main Results:

• Anthracyclines and trastuzumab are significant causes of chemotherapy-related cardiac toxicity.
• Management strategies focus on risk mitigation and early detection.
• Serial monitoring of cardiac function is the cornerstone of managing cardiotoxicity.

Conclusions:

• Cardiac toxicity from anti-cancer drugs requires vigilant monitoring and management.
• Early detection through regular cardiac function assessment is critical for preventing severe outcomes.
• Ongoing research into cardiotoxicity of novel cancer therapies is essential.